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antiresorptive agents against each other didn’t evidence a statistically signiﬁcant 
difference. ConClusions: The results of this MTC can suggest that Risedronate, 
compared to placebo, is expected to provide the highest rate of reduction in NVF in 
women affected by postmenopausal OP. However, the mixed treatment comparisons 
among alendronate, risedronate, ibandronate, zolendronate and denosumab did not 
evidence a statistically significant difference.
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lower extreMitieS
Steinhausz V1, Sió E1, Gombos G1, Bajsz V1, Tóth E2, Sömjén K3, Ács P4, Boncz I4
1University of Pécs, Zalaegerszeg, Hungary, 2Budai Physiotherapy Clinic, Budapest, Hungary, 
3Elisabet Hospital, Zirc, Hungary, 4University of Pécs, Pécs, Hungary
objeCtives: The Start Excursion Balance test (SEBT) is commonly used to assess 
the dynamic stability of the trunk and lower extremities in which eight times three 
(8x3) measurements are made, this means a total of 48 measurements on the two 
sides. The aim of this research is to create a simpler and faster balance test and 
to compare this with other validated balance tests. Methods: The study was 
implemented in August 2014 at the University of Pécs Faculty of Health Sciences 
Zalaegerszeg Training Centre in which 11 adult and 30 youth basketball players play-
ers were involved (mean age: 14.9 year, mean height: 179.9cm). The Dynamic Lateral 
Balance Test (DLBT) is based on a newly developed methodology and use a simple 
calliper to measure the values. To assess the strength of the relationship between 
the specific tests ( SEBT, Flamenco Test and DLBT) Pearson correlation coefficients 
were computed. Statistical significance was established at the α -level of 0.05 for all 
analyses, and IBM SPSS, Inc., 20.0v was used. Results: We found moderate cor-
relation between the values of the DLBT and the body height(p< 0.001), therefore we 
expressed the values correlated with body height(DLBT / body height x 100). There 
wasa moderate negative correlate between the values of the Flamenco Test and 
the DLBT test (left side: r = -0.424, p = 0.006; right side: r = -0.432, p = 0.005). There 
was a moderate positive correlation between the DLBT and the SEBT regarding 
some directions (p < 0.05), for example: right DLTB – right posteromedial: r = 0.480, 
p = 0.002; left DLBT – left posteromedial: r = 0.491, p = 0.002. ConClusions: The 
present pilot study confirmed the correlation between the newly developed DLBT 
and other validated tests; consequently this new test can become a fast, simple and 
informative solution for testing the dynamic balance.
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objeCtives: Psoriasis and Psoriatic Arthritis (PsA) are chronic, inflammatory, 
autoimmune diseases that negatively impact on health-related quality of life. 
The aim of this study was to analyze the healthcare profile and the overall cost 
of patients with Psoriasis/PsA in the real clinical practice. Methods: From 
ARNO Observatory database we carried out a record linkage analysis of disease 
exemptions, drug prescriptions and specialist services on 2.988.195 subjects, with 
available, complete and good quality data. Patients with Psoriasis/PsA were col-
lected from 01/01/2009 to 31/12/2011 (accrual period) and followed up to 2 years, 
to analyze specific treatments (DMARDs, biological, topical), therapy switches, 
community and hospital cares and their expenditure (mean/patient). Results: 
Of 2.988.195 subjects, 6.030 met two or more inclusion criteria (53% men, mean 
age 54,5±14,6 years). During the 2-year follow-up non-biological and biological 
drugs were prescribed respectively to 2.738 (45%) and to 902 (15%) patients. 591 
took both: 390 (66%) started DMARDs then switched to biological treatments in 7±6 
months on average. 2.783 (46%) patients received “other drugs”, mostly NSAIDs, 
Corticosteroids (systemic and dermatological use), Penicillins and Quinolone anti-
bacterials. 950 patients (16%) were discharged from ordinary and daily hospitaliza-
tions mainly for skin, connective tissue and cardiovascular (CVD) diseases. CVD 
and Neoplasia (8195€ /patient/2-year follow-up) were between the most expensive 
causes of ordinary admissions. Psychiatric disorders caused the longest stay in-
hospital (33,5 mean days/patient). 51,5% of patients received specialist healthcare 
services (blood count and liver enzymes). Patients treated with biological drugs 
were more expensive than those treated with DMARDs and topical therapies, for 
pharmaceutical, in-hospital and specialist cares (7.978€ /patient/year of follow-
up). ConClusions: This assessment of healthcare profiles of patients with 
Psoriasis/PsA in the real in-hospital and community Italian settings provided 
evidence that patients treated with biological therapies are those with a more 
compromised health that induces high costs on all aspects of their care.
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objeCtives: The epidemiology and treatment patterns of osteoporosis are poorly 
understood in Portugal. Available evidence suggests that many post-menopausal 
(PM) women with osteoporosis are not pharmacologically treated for this condi-
tion (i.e. under-treatment). Furthermore, high levels for treatment discontinua-
tion (i.e. non-persistence) are still reported in the clinical practice. We aimed to 
describe the treatment patterns of PM osteoporosis and to understand reasons for 
under-treatment and non-persistence in Portugal. Methods: This is an observa-
tional, cross-sectional study, nested in a patient registry database developed by the 
Portuguese Society of Rheumatology, and conducted during 2014. Complementary 
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objeCtives: For patients with polyarticular juvenile idiopathic arthritis (pJIA), a 
published indirect comparison1 demonstrated that abatacept, adalimumab and 
etanercept are similarly efficacious, as measured by preventing disease flare after 
response to treatment. The objective of this study was to indirectly assess the effi-
cacy and safety of abatacept, adalimumab and etanercept compared to tocilizumab 
in patients with pJIA. Methods: There have been no head-to-head trials comparing 
biological disease modifying anti-rheumatic drugs (bDMARDs) in patients with pJIA. 
A published systematic review and indirect comparison did not include tocilizumab. 
Therefore, we conducted an indirect comparison, using the Bucher method, to esti-
mate the efficacy of tocilizumab compared with the other bDMARDs. The definition 
of pJIA and baseline characteristics of patients in the tocilizumab trial were similar 
to the trials included in the published study. We also compared the incidence of 
serious adverse events (SAEs) during the double-blind phase of the trials for each 
bDMARD versus placebo using Fisher’s exact test. Results: The relative risk of 
preventing disease flare after response to treatment for abatacept, adalimumab and 
etanercept versus tocilizumab in patients with pJIA was 0.71 (95% CI: 0.35-1.43), 1.10 
(95% CI: 0.64-1.91) and 0.65 (95% CI: 0.30-1.43), respectively. The incidence of SAEs 
for each bDMARD was not significantly different when compared to placebo, with 
Fisher’s exact test p-value as 0.50, 0.49, 0.24 and 1.00, for abatacept, adalimumab, 
etanercept, and tocilizumab, respectively. ConClusions: We conclude that abata-
cept, adalimumab, etanercept and tocilizumab have comparable efficacy in pJIA 
in preventing disease flare after response to treatment. The incidence of SAEs for 
each bDMARD was not statistically significantly different from that of placebo, 
and therefore was likely to be generally comparable between the bDMARDs. As the 
efficacy and safety of these bDMARDS are comparable, cost-minimisation analysis 
is an appropriate method for economic evaluation of these treatments. 1 Otten MH, 
et al. AnnRheumDis 2013;72:1806–1812
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objeCtives: Rheumatoid arthritis (RA) is a chronic disease characterized by 
inflammation of the synovial tissue leading to joint destruction. The introduction 
of biologic agents dramatically changed the prognosis of RA, especially when admin-
istered in early RA (ERA). At now there are 8 different biologic agents approved 
for the therapy of ERA. The aim of this Bayesian metanalysis is to compare and 
rank biologics indicated for ERA. Methods: A literature search was performed 
to identify articles reporting data from RCTs on the use of biologic approved for 
ERA. MTC results are reported as the relative risk of response (RR), intended as 
the capacity of inducing an ACR20, ACR50 and ACR70 response for each biologic 
associated to MTX compared with MTX. Results: A total of 10 scientific papers 
were identified. Studies differed for length of followup and consequently only data 
at 12 weeks were taken into account. All biologic agents, associated to MTX, proved 
to be more efficacious in inducing an ACR20, ACR50 and ACR70 response respect to 
MTX. When comparing results obtained by different drugs, Etanercept proved to be 
the biologic agent that represents the best choice for obtaining ACR20 and ACR50 
response with a probability of 62,95% and 37,1% respectively, while Adalimumab 
represents the best choice for inducing ACR70 response with a probability of 
33,28%. ConClusions: In our MTC on RCTs on the use of biologic agents used 
in ERA, we identified Adalimumab as the more probably best choice in obtaining 
the result of ACR70 response and for such reason this drug should be considered 
as a first line therapy in patients affected by ERA. Etanercept proved to be the more 
probably best choice in obtaining ACR50 and ACR20 response, and for such reason 
it should be considered as the second line choice in patients affected by early RA.
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objeCtives: Osteoportic non Vertebral fractures (NVF) resulted the more frequent 
kind of fracture in large population studies, with a severe incidence on annual 
costs for the health system and an increased risk of death for fractured patients. 
The burden of fracture is expected to increase with an ageing population. Data 
from head to head RCT focused on reduction of incidence of non vertebral frac-
ture among available antiresorptive agents are not availabe. This MTC aims to 
compare alendronate, risedronate, ibandronate, zolendronate and denosumab on 
completion of preventing osteoporosis NVF in a Bayesian metaanalysis assessing 
indirect comparisons. Methods: A systematic research for RCT involving alen-
dronate, risedronate, ibandronate, zolendronate and denosumab was conducted 
using databases (CENTRAL, CINAHL,Embase, HMIC, MEDLINE and PsycINFO). MTC 
results are reported as the relative risk of response (RR), intended as the capacity 
of reducing NVF for each antiresorptive agent compared with placebo. Results: 
Nine RCTs were identiﬁed. Three trials compared Alendronate versus placebo, 2 
trials compared Risedronate vs placebo, 2 trials Zolendronate vs placebo, and one 
trial for ibandronate and denosumab. Risedronate had the highest probability (72%) 
of being the most effective treatment, followed by Zolendronate (22%), Denosumab 
(4,60%) and then alendronate (1%) and ibandronate (0.10%). Comparisons of any 
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objeCtives: Patients with RA have a higher risk of ischemic cardiac events com-
pared with the general population. This would be explained not only by the greater 
presence of traditional risk factors, but also by the systemic inflammatory nature 
of the disease. Compare self-reported prevalence of risk factors in rheumatoid 
patients with prevalence data from the brazilian general population. Methods: 
Cross-sectional study between July and November 2014 including 183 patients with 
rheumatoid arthritis of both sexes, aged 20 years or older, in primary or secondary 
care units of the city of Blumenau, southern Brazil. Data collection was conducted 
through structured personal interview and, if needed, later complemented by phone. 
The national survey Vigitel 2012 was used to collect data from brazilian general 
population. Results: The target population consisted of 183 patients, 153 (83.6%) 
were female, mean age of 56.9 years and mean duration of disease of 12.1 years. The 
prevalence of self-reported comorbidities of the target population when compared 
with general population prevalence was respectively: hypertension 44.8% versus 
28.3%, diabetes mellitus 9.2% versus 12.5%, dyslipidemia 22.9% versus 16.5%, over-
weight 41.5% versus 35.8% and obesity 18.5% versus 19.1%, prior smoking 45.9% ver-
sus 23.4%, current smoking 8.7% versus 12.8%, physical inactivity 65% versus 14.2%. 
Positive family history for cardiovascular disease was observed in 42% of rheumatoid 
patients, that shows mean body mass index of 26.3 kg/m2. ConClusions: The 
study result shows that the self-reported prevalence of traditional risk factors for 
ischemic heart disease in patients with rheumatoid arthritis in Blumenau is higher 
than the national prevalence of hypertension, dyslipidemia, overweight, previous 
smoking and physical inactivity. By contrast, the prevalence is lower for diabetes 
mellitus and current smoking.
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objeCtives: To examine the resource utilization and direct costs of care in severe 
spondyloarthritis (SpA) patients based on a national representative claims data-
base. Methods: The EGB Database is a national representative random sample of 
1 out of every 97 individuals covered by the main French public health insurance 
schemes, listing all healthcare consumption and allowing identification of beneficiar-
ies eligible for full health insurance coverage due to severe conditions. The annual 
economic burden related to severe SpA was estimated by comparing direct medical 
expenses (outpatient care and hospitalization costs) in the SpA adult (≥ 18 years) 
population to a control group (i.e. patients not in “Affection de Longue Durée” for 
severe SpA in 2012) matched for age and sex, using non-parametric Mann-Whitney 
tests. Overall cost (healthcare utilization and associated costs) was assessed from 
the Health Insurance perspective for 2012. Results: Among 470,326 adults in the 
database, 827 patients presenting with severe SpA were identified, corresponding to 
a nationwide prevalent population estimate of 88,275 patients in France in 2012. High 
blood pressure, recurrent major depressive disorders and other comorbidities taken as 
a whole were significantly more frequent in severe SpA patients than controls (4.5% 
vs 1.8%, p< 0.0001; 3.1% vs 1.5%, p= 0.003 and 24.7% vs 18.8%, p= 0.0003, respectively). 
Annual medical costs per severe SpA patient were 3.5 times higher than that of 
controls (mean costs: € 6,122±8,179 vs € 1,682±5,769, p< 0.0001; median costs: € 2,519 
vs € 300). The main contributors to this incremental cost were (mean values): medica-
tions (+€ 2,390, 53.8%), hospitalization (+€ 1,038, 23.4%) and healthcare professional 
consultations (+€ 716.7, 16.2%). The annual economic burden related to severe SpA in 
France in 2012 is estimated around € 391M. ConClusions: The burden of severe SpA 
is significant in France with regard to comorbidities and medical costs supported by 
the healthcare system, as identified in this representative database analysis.
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objeCtives: The changes of vitamin D level influencing bone metabolism are sea-
sonal, the effect of seasons on femoral neck fracture healing is unknown. The aim of 
our study was to determine the effects of seasonal periodicity on incidence of oste-
onecrosis following primary osteosynthesis of femoral neck fractures in Hungarian 
elderly population. Methods: This nationwide retrospective observational cohort 
study based on dataset of National Health Insurance Fund Administration. Patients 
over 60 years undergoing internal fixation after primary femoral neck fracture 
(ICD10-S7200) and were discharged in 2000 were identified. Inpatient cases devel-
oping osteonecrosis were registered during the 8 years follow-up. The following 
factors were evaluated: sex, age, type of fracture, season of surgical intervention, 
day of surgery, surgical delay and comorbidities. The effect of seasons on survival 
time was investigated by Kaplan–Meier analysis and log-rank test. The crude inci-
dence rate ratios of osteonecrosis were calculated for factors. The impact of risk 
factors on the hazard of osteonecrosis was estimated by Cox proportional hazard 
model. Results: 3312 patients fit the criteria. During the observation period 106 
osteonecrosis (3.2%) were identified, yielding an overall incidence 8.87 per 1000 
person-years. The crude incidence rates were 14.38, 8.57, 6.58, and 5.70 per 1000 
person-years in winter, spring, summer, and fall. No significant differences were 
found in survival with respect to season with Kaplan–Meier analysis (p= 0.173). 
data was collected via phone calls through a specific questionnaire answered by 
PM women aged ≥ 50 years old (yo) who were in the registry and contacted directly 
by SPR researchers. Results: We surveyed 1.587 PM women with a mean age of 
66.0 yo (SD= 9.2). 43% had PM osteoporosis, but only 38.4% of women had previous 
knowledge of it. Previous diagnosis was mostly done by primary care physicians 
(57.9%). Less than a tenth (9.1%) had osteoporosis treatment. The most common 
pharmaceutical treatment was oral bisphosphonates (19.8%), followed by stron-
tium ranelate (7.8%). 199 women (12.5%) had stopped osteoporosis treatment in the 
12-month period previous to the questionnaire. This decision was driven by patients 
(61.3%) followed by the physicians (36.2%) and self-reported reasons were economic, 
polymedication, efficacy, gastrointestinal adverse events and other safety concerns. 
Of special interest, gastrointestinal adverse events were self-reported by more than 
a third of those women ever treated for osteoporosis (36.1%). This led to more health-
care consumption and treatment changes. ConClusions: In this report, using a 
large sample from a patient registry, we observed low rates of treatment and high 
levels of therapy discontinuation in Portugal. A further understanding of underlying 
reasons for under-treatment and non-persistence is crucial to attain better health 
outcomes in post-menopausal osteoporosis.
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objeCtives: Osteoporosis and chronic inflammatory rheumatic diseases (CIRD), 
including rheumatoid arthritis (RA), psoriatic arthritis (PA) and ankylosing spon-
dylitis (AS), are major issues in rheumatology. In these two therapeutic areas, data 
are needed to describe burden of disease and clinical management. Our objective 
was to identify patients likely to have osteoporosis or CIRD within French claims 
database, before running analyses. Methods: As there is no diagnosis code in the 
database, treatment pattern or medical resource utilization were used to identify 
patients. Patients with osteoporosis were identified using age (≥ 50), reimbursement 
of anti-osteoporotic agents (ATC codes), osteoporosis-related hospitalization, or 
Long Term Disease (LTD) status, based on ICD-10 codes. For CIRD, the study popula-
tion included 3 sub-groups: patients with RA, PA and AS. For AS, identification was 
based on hospitalizations and LTD status for ICD-10 codes M08.1, M08.8, M08.9, 
M45, and M46. Identification for RA was based on ICD-10 codes M05, M06, M08.0, 
M08.2, M08.4 and M13. Identification for PA was based on ICD-10 codes M07 and 
M09. Results: Identification criteria for osteoporosis allowed to identify 7,939 
patients, corresponding to 4.5% of the French population ≥ 50 years. This popula-
tion consists of 92% of women and mean age is 71.6 years. Identification criteria 
selected 2,070 for RA, 923 patients for SA, and 492 patients for RP, corresponding 
to 3,223 patients with CIRD disease (0.62% of French population) ConClusions: 
4.5% of patients of the French population have osteoporosis based on our selection 
criteria; a majority are old women, in line with the literature. For CIRD, 3,223 patients 
were identified, which is also consistent with the literature. Next steps will include 
the description of treatment patterns and the burden of  disease.
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objeCtives: In France, the ECLAIR non-interventional, multicenter study was 
initiated to follow up real-world, moderate-to-severe, active RA patients treated 
with certolizumab pegol (CZP), prospectively for up to 3 years. In 2003, prescrip-
tion of glucocorticoids (GCs) in French patients with active RA was evaluated,1 
showing that > 50% received GCs, although GC use has not been comprehensively 
studied to date.1The objective is to describe baseline characteristics of French 
RA patients starting CZP, such as disease and treatment history, and concomi-
tant medication. Methods: The ECLAIR study, run by 170 rheumatologists and 
6 internal medicine specialists, was designed to be representative of the French 
RA population. Baseline data, collected from treating physicians and patients via 
questionnaires, included history of RA treatments and concomitant diseases and 
their treatments. Results: 791 patients were included: 790 were used for analysis, 
1 was excluded for lack of signed informed consent. Patient characteristics: mean 
(SD) age 55.0 (13.1); 78.7% female; RA duration 8.9 (9.1) years; 73.4% rheumatoid 
factor positive; DAS28(ESR) 4.9 (1.3); disease activity moderate for 50.1% and high 
for 41.1% of patients. Mean HAQ-DI total score: 1.28 (0.69). Concomitant diseases: 
23.2% (183/790) of patients had vascular disorders, 19.1% (151/790) metabolism and 
nutrition disorders and 17.5% (138/790) musculoskeletal and connective tissue dis-
orders. Concomitant treatments included NSAIDs in 35.2% of patients, steroids in 
51.4% of patients and cDMARDs in 64.6% of patients (MTX: 53.5%, leflunomide: 9.0%, 
hydroxychloroquine: 2.8%, sulfasalazine: 2.4%, azathioprine: 0.3%, thalidomide: 
0.1%). ConClusions: ECLAIR is the first anti-TNF, prospective, real-world study 
conducted in France, providing insights into the population of RA patients treated 
with anti-TNF therapy such as CZP. Baseline data showed that half of patients on 
CZP received GCs, similar to previous reports in the French RA population.1Further 
targeted statistical analyses on ECLAIR data could clarify trends associated with 
concomitant medication. REFERENCES: 1. Saraux A. J Rheumatol 2006 Jul;33:1258-6
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